Epstein-Barr virus infection has been associated with lymphoepithelioma-like carcinoma of the lung in Asian patients. Recently, Epstein-Barr virus proteins or genomic DNAs were detected in pulmonary squamous-cell carcinoma, adenocarcinoma, and undifferentiated small-cell carcinoma in American patients. We studied 23 cases of small-cell carcinoma of the lung for evidence of Epstein-Barr virus infection by in situ hybridization, immunohistochemistry, and polymerase chain reaction methods. Of the 23 cases, 13 cases were primary smallcell carcinoma of the lung and 10 cases were metastatic small-cell carcinoma of the lung to the brain (one case), liver (two cases), and lymph nodes (seven cases). None of the 23 cases was positive for Epstein-Barr virusencoded small nonpolyadenylated RNA (EBER)-1 by in situ hybridization. By immunohistochemistry, eight cases showed focal positivity for Epstein-Barr virus nuclear antigen-1. The positive immunostaining was focal and was observed in tumor cells, vascular endothelial cells, and lymphocytes, suggesting nonspecific staining. None of the 23 cases was positive for the transactivating immediate-early BZLF1 (ZEBRA) and latent membrane protein (LMP-1). Only one case was positive for the BamHI W region and LMP-1 gene by polymerase chain reaction assay. Some tumor cells in the BamHI W region positive case were also positive for Epstein-Barr virus nuclear antigen-1. Our study indicates that rare cases of American small-cell carcinoma of the lung may contain Epstein-Barr virus-infected cells, but it is unlikely that Epstein-Barr virus plays a role in the tumorigenesis of small-cell carcinoma of the lung.
Epstein-Barr virus has been associated with several human epithelial neoplasms, including nasopharyngeal carcinoma, 1 gastric carcinoma, and lympho epithelioma-like carcinomas from the stomach, 2 salivary gland, 3 head and neck, [4] [5] [6] and gallbladder. 7 Pulmonary carcinomas with morphologic features of lymphoepithelioma-like carcinoma have also been reported to harbor Epstein-Barr virus. [8] [9] [10] [11] Most of these reports of Epstein-Barr virus-associated epithelial malignancies were in Asian patients. In contrast, there are few reports demonstrating EpsteinBarr virus infection in pulmonary carcinoma in Western populations. Huber et al 12 reported a case of pulmonary adenocarcinoma with signet-ring-cell features harboring Epstein-Barr virus by EBER-1 in situ hybridization and BamHI W region polymerase chain reaction methods. Using Epstein-Barr virus nuclear antigen-1 immunohistochemistry, Grinstein et al 13 recently found that two of the 22 cases of pulmonary squamous-cell carcinoma and two of the 10 cases of pulmonary neuroendocrine carcinoma were positive for Epstein-Barr virus. Finally, Hartmann et al 14 found 11 of the 15 cases of the lung undifferentiated small-cell carcinoma to be positive for Epstein-Barr virus by immunohistochemistry, in situ hybridization and polymerase chain reaction methods.
Small-cell carcinoma of the lung comprises approximately 15% of all pulmonary cancers. At least 85% of patients are smokers. However, only a minority of smokers develop small-cell carcinoma of the lung. Additional factors may play a role in the development of small-cell carcinoma of the lung. As suggested above, Epstein-Barr virus has been proposed to play such a role in the tumorigenesis of small-cell carcinoma of the lung. Therefore, we studied Epstein-Barr virus infection in 23 cases of American small-cell carcinoma of the lung using a large battery of techniques, including in situ hybridization (EBER-1), immunohistochemistry (LAMP-1, ZEBRA, and Epstein-Barr virus nuclear antigen-1) and polymerase chain reaction (LMP-1, Epstein-Barr virus nuclear antigen-4 and BamHI W region) methods.
Materials and methods

Patients and Tissue Samples
In all, 23 cases of small-cell carcinoma of the lung (primary, 13 cases; and metastatic, 10 cases) were retrieved from the surgical pathology files at the Department of Pathology at City of Hope National Medical Center (11 cases) and at the Department of Pathology at the University of Virginia (12 cases) ( Table 1 ). The tissues had been routinely fixed in 10% neutral formalin and embedded in paraffin. One paraffin tissue block with tumor was selected from each case. Several 4 mm sections were cut from each case.
EBER-1 In situ Hybridization
The in situ hybridization methods have been previously described. 15 Briefly, we used a probe from a region of the Epstein-Barr virus genome that is actively transcribed in latently infected cells, a 30-base oligonucleotide complementary to a portion (69-98 bp) of the EBER-1 gene. The sequence was 5 0 -AGA CAC CGT CCT CAC CAC CCG GGA CTT GTA-3 0 (Operon Technologies, San Pablo, CA, USA). The probe was labeled with biotin at its 3 0 end. Paraffin sections were deparaffinized and digested with pronase (nuclease-free). Sections were incubated with prehybridization solution and then hybridized with sheared salmon sperm and yeast tRNA along with the appropriate amount of probe. The probe was used at a concentration of 0.25 ng/ml with overnight hybridization. Sections were then incubated in a solution of avidin-alkaline phosphatase conjugate, washed for 3 min, incubated in McGadey's substrate, briefly washed in distilled water, air dried, and coverslipped. No counterstain was used. A poly-d(T) was used as a control for total RNA preservation, while a known Epstein-Barr viruspositive case of nasopharyngeal carcinoma was used as a positive control. A case was considered positive if the nucleus, or the nucleus and cytoplasm, of a tumor cell stained dark blue or black.
Epstein-Barr Virus Nuclear Antigen-1, LMP-1, and ZEBRA Immunohistochemistry Dr Grasser 16 (Abteilung Virologie, Institut fur Medizinische Mikrobiologie und Hygiene and Institut fur Pathologie, Universitaatakliniken des Saarlandes, Homburg, Germany) kindly provided the rat monoclonal antibody clone 2B4 to Epstein-Barr virus nuclear antigen-1. We also used two other antibodies, mouse monoclonal antibody clones CS1-4 to LMP-1 protein (Dako Corporation, Carpinteria, CA, USA) and clone BZ.1 to ZEBRA (BamHI Z fragment, Epstein-Barr-replication activator) protein (Dako). Epstein-Barr virus nuclear antigen-1, LMP-1, and ZEBRA immunohistochemistry were performed in all 23 cases of small-cell carcinoma of the lung. Paraffin sections were deparaffinized and rehydrated in a graded alcohol series. Two of the antibodies (LMP-1 and ZEBRA) required heat-induced epitope retrieval using 100 mM EDTA buffer (pH 8.0) or 10 mM citrate buffer (pH 6.0), for Epstein-Barr virus nuclear antigen-1 and ZEBRA, respectively, in a steamer (Black and Decker, Shelton, CT, USA) at 1001C for 20 min. The sections were then incubated with 2B4 at 1:500 dilution at room temperature overnight, with CS1-4 at 1:320, or with BZ.1 at 1:20 dilution at room temperature for 40 min and washed three times (5 min each) with PBS buffer. The sections were then incubated with a biotinylated goat, anti-rat antibody (Vector Laboratories, Burlingame, CA, USA) (for Epstein-Barr virus nuclear antigen-1) at a dilution of 1:150, or biotinylated goat, anti-mouse/anti-rabbit antibody (Ventana Medical Systems, Tucson, AZ, USA) (for LMP-1 and ZEBRA) at a dilution of 1:8, followed by the application of two washes (5 min each) of PBS buffer. EnVision Plus (Dako) and peroxidase detection methods were used.
Polymerase Chain Reaction Studies for LMP-1, Epstein-Barr Virus Nuclear Antigen-4 and BamHI W Region Viral genomic DNA was extracted from formalinfixed, paraffin-embedded tumor tissues, using 0.2 mg/ml. proteinase K digestion buffer overnight, followed by denaturation by boiling. The polymerase chain reaction studies were performed with 2 ml of extracted DNA in a 30 ml mixture containing 50 mmol/l KCl, 10 mmol/l Tris buffer (pH 8.3), 50 mm of each deoxynucleotide triphosphate, 2.5 mmol/l MgCl 2 , 1 U of Taq polymerase (Perkin Elmer, Foster City, CA, USA) and 20 pmol of each primer. The primers for BamHI W region were: 3 0 -CGGTCGCCCAGTCCTACCAG-5 0 and 5 0 -CCTGGA GAGGTCAGGTTACT-3 0 . 17 The expected BamHI W region PCR product size was 125 bp. We used primers for Epstein-Barr virus nuclear antigen-4 that flank the DNA region coding for epitopes of 399-408 and 416-424 of the prototype B95. -GTG GGG GTC GTC ATC  ATC TC-3 0 . After initial denaturation for 5 min at 951C, 45 amplification cycles were performed as follows: denaturing at 941C for 30 s, annealing at 581C for 30 s, and extension at 721C for 40 s. A final extension at 721C for 7 min completed the polymerase chain reaction amplification. The polymerase chain reaction setup and the post-polymerase chain reaction work were performed in separate laboratories to minimize the possibility of contamination. The BamHI W, Epstein-Barr virus LMP-1, and Epstein-Barr virus nuclear antigen-4 polymerase chain reaction products were separated by agarose gel electrophoresis and transferred on to a nitrocellulose membrane. The BamHI W region polymerase chain reaction product was then hybridized with BamHI W region-specific probe 5 0 -GGGGACTTC CACTTGGCGAA-3 0 . The LMP-1 polymerase chain reaction product was hybridized with LMP-1 probe 5 0 -CCGGAACCAGAAGTACCCAA-3 0 . The EpsteinBarr virus nuclear antigen-4 polymerase chain reaction product was hybridized with Epstein-Barr virus nuclear antigen-4 probe 5 0 -ACTGCCGTA CAATCCAACAG-3 0 .
Results
Clinical Features
All 23 patients were Caucasians. Of the 23 cases, 18 were resection specimens, and five were needle-core biopsy specimens.
In situ Hybridization for EBER-1
Sections of all 23 cases of small-cell carcinoma of the lung were hybridized with poly-d(T) and EBER-1.
All the cases showed strong nuclear positivity for poly-d(T) (control for RNA preservation). None of the 23 cases was positive for EBER-1 ( Figure 1 , Table 1 ). and b-globulin (the latter, a control for DNA preservation). Strong b-globin amplified bands were identified from all the 23 cases, indicating that the quality and quantity of the purified DNAs were good. One of the 23 cases showed an amplified BamHI W region (Figure 1 ). Some tumor cells in this case had shown nuclear positivity for 2B4 by immunohistochemistry, but was negative by other assays (Figure 1 ). One other case was polymerase chain reaction positive for the LMP-1 gene region. 
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Discussion
Several studies have demonstrated Epstein-Barr virus genome in pulmonary carcinomas with morphologic features of lymphoepithelioma-like carcinoma in Asian pattents [8] [9] [10] [11] and Western populations. 12 We studied Epstein-Barr virus RNA in 78 cases of pulmonary nonlymphoepitheliomalike carcinoma using in situ hybridization methodology in 1992, and found none of them to be positive for Epstein-Barr virus. 15 In contrast, several recent studies reported that Epstein-Barr virus gene products were detected in pulmonary nonlymphoepithelioma-like carcinoma, such as pulmonary squamous cell carcinoma and neuroendocrine carcinoma 13 and small-cell carcinoma of the lung.
14 It is necessary to use a large battery of molecular and immunohistochemical methods to investigate whether Epstein-Barr virus plays any role in pulmonary nonlymphoepithelioma-like carcinoma.
EBER in situ hybridization has been regarded as 'gold standard' for the identification of a significant association of Epstein-Barr virus with a given neoplasm. 18 Unlike Epstein-Barr virus nuclear antigens and LMPs, EBERs are theoretically expressed in all three types of Epstein-Barr virus latent infection. Epstein-Barr virus-infected cells usually contain a large number of EBER copies, on the order of 10 5 -10 6 , therefore EBER in situ hybridization should be the most sensitive method to detect any type of Epstein-Barr virus infection in tumor cells. Most importantly, by direct visualization of positive cells, one can determine whether tumor cells or normal lymphocytes are positive for Epstein-Barr virus. However, several recent studies have cast doubt on the ability of EBER in situ hybridization studies, [19] [20] [21] although other subsequent studies have not confirmed this finding. [22] [23] [24] In the current study, we also performed polymerase chain reaction analysis using two separate target regions. The BamHI W region is iterated 7-12 times in the Epstein-Barr virus genome, thus providing a particularly good target for the detection of EpsteinBarr virus in a sample in which a small viral copy number might be expected. 25 However, visualization of the positive cells is not possible using polymerase chain reaction analysis. Approximately one in 10 5 -10 6 of the B lymphocytes purified from the peripheral blood of previously infected people are latently infected with Epstein-Barr virus. 26, 27 Other studies of normal lymphoid tissues have shown between one in 1000 to one in 10000 infected cells. 28 When DNA is extracted from tissue for polymerase chain reaction studies, Epstein-Barr virus DNA from Epstein-Barr virus infected B-cells may be potentially amplified, leading to a 'false'-positive polymerase chain reaction result. Therefore, polymerase chain reaction studies alone do not provide definitive evidence of Epstein-Barr virus within neoplastic cells, as one cannot exclude the possibility that Epstein-Barr virus within 'bystander' lymphocytes contributes the positive signal.
Immunohistochemical demonstration of EpsteinBarr virus nuclear antigen-1 expression may provide additional evidence that a given tumor is EpsteinBarr virus positive. Similar to other studies in the literature, 13, 19 we also used Epstein-Barr virus nuclear antigen-1 antibody 2B4 clone in our study, which was produced against a lambda-cro/lacZEpstein-Barr virus nuclear antigen-1 fusion protein that had been shown to react in all forms of EpsteinBarr virus latency. 16 This antibody had been previously demonstrated to have nearly equal sensitivity in paraffin or frozen section immunohistochemistry. However, the current study as well as some of the previous studies have suggested that the specificity of the 2B4 clone may not be absolute. 23, 29 The irregular GGGGCAGGA repeat motifs of the latent infection cycle Epstein-Barr virus nuclear antigen-1 gene are interspersed in cellular DNA. Monoclonal antibodies to the irregular glu and ala repeating peptide motifs of Epstein-Barr virus nuclear antigen-1 may theoretically cross-react with cell protein. 30 Moreover, two cell proteins can specifically bind to the Epstein-Barr virus nuclear antigen-1 cognate DNA sequence. 31 Thus, at least part of the Epstein-Barr virus nuclear antigen-1 reactivity with antibodies may have arisen from this cellular DNA interaction. Therefore, at present, we do not consider Epstein-Barr virus nuclear antigen-1 immunohistochemical positivity as a sole finding as evidence of Epstein-Barr virus infection, in the absence of other confirmatory studies, in particular EBER in situ hybridization. We think that at this time, at least two different techniques, including at least one providing cellular localization to the tumor cells should be found to be positive, before one can consider that a particular neoplasm may be truly Epstein-Barr virus associated.
Of the 23 cases of American small-cell carcinoma of the lung studied by us, we found nine cases with Epstein-Barr virus positivity by at least one technique. Seven of these cases were positive by EpsteinBarr virus nuclear antigen-1 staining alone, without confirmation using a second methodology. In these cases, the percentage of positive tumor cells was low and there was an additional staining of endothelial cells and lymphocytes. We consider this to be falsepositive staining since polymerase chain reaction analysis was completely negative in seven of the eight cases, and in the eighth case, only the highly sensitive BamHI W PCR was positive, possibly reflecting 'contamination' by Epstein-Barr virus infected B-lymphocytes. We did not find any case to be positive by EBER-1 in situ hybridization, including either the BamHI W region positive case (case 8) or the LMP-1-positive case (case 9). Eight cases with a variable number of tumor cells being positive for Epstein-Barr virus nuclear antigen-1 stain were interpreted as false-positive (nonspecific staining) because a similar Epstein-Barr virus nuclear antigen-1 nuclear staining was also found in vascular endothelial cells and lymphocytes in same cases and the positive Epstein-Barr virus nuclear antigen-1 staining did not show any correlation with the results of EBER-1 in situ hybridization. There was only one case (case 8) that had Epstein-Barr virus nuclear antigen-1 positive cells and was positive with another technique (polymerase chain reaction for the BamHI W region), and this case was negative by all other analyses, including two other polymerase chain reaction assays. We believe that the BamHI W region positivity by polymerase chain reaction in this case most likely represents contamination by host lymphocytes that was detected due to the exquisite sensitivity of the assay.
In summary, after studying 23 cases of small-cell carcinoma of the lung using most sensitive and specific methods, we did not find convincing evidence of Epstein-Barr virus infection. Although some cases of small-cell carcinoma of the lung may be positive, Epstein-Barr virus by polymerase chain reaction and some cells of small-cell carcinoma of the lung may be positive for Epstein-Barr virus nuclear antigen-1 by immunohistochemical assays, these results in isolation are not sufficient to conclude pathogenetic significance. Epstein-Barr virus nuclear antigen-1 immunohistochemistry or polymerase chain reaction assay alone cannot be used as the only method to determine Epstein-Barr virus status in a given tumor.
